CoChat

Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Adeno-associated virus (AAV) is one of the most extensively studied and utilized viral vectors in clinical gene transfer research. However, the serum instability and immunogenicity of AAV vectors significantly limit their application. Here, we endeavored to overcome these limitations by developing a straightforward approach for site-specific PEGylation of AAV via genetic code expansion. This technique includes incorporation of the azide moiety into the AAV capsid protein followed by orthogonal and stoichiometric conjugation of a variety of polyethylene glycols (PEGs) through click chemistry. Using this approach, only the chosen site(s) was consistently PEGylated under mild conditions, preventing nonselective conjugation. Upon a series of in vitro examinations, AAVs conjugated with 20-kD PEG at sites Q325+1, S452+1, and R585+1 showed a 1.7- to 2.4-fold stability improvement in pooled human serum and a nearly twofold reduction in antibody recognition. Subsequent animal research on Sprague Dawley rats displayed a promising 20% reduction in antibody inducement and a higher virus titer in the blood. Together, our data demonstrate successful protection of an AAV vector from antibody neutralization and blood clearance, thereby increasing the efficiency of therapeutic gene delivery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules22071155

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Diagram of precision PEGylation of adeno-associated virus 2 (AAV-2) to protect against recognition and degradation by neutralizing antibodies and proteases. The AAV-2 vector was site-specifically labeled with azide-bearing amino acids and then modified with polyethylene glycols (PEGs) via a bioorthogonal reaction to achieve preferable serum stability.
Figure 1 Diagram of precision PEGylation of adeno-associated virus 2 (AAV-2) to protect against recognition and degradation by neutralizing antibodies and proteases. The AAV-2 vector was site-specifically labeled with azide-bearing amino acids and then modified with polyethylene glycols (PEGs) via a bioorthogonal reaction to achieve preferable serum stability.CC BY · PubMed Central
Figure 2 Feasibility of site-specific PEGylation of AAV capsid protein VP1 and AAV vectors by incorporation of NAEK (Nε-2-azideoethyloxycarbonyl-L-lysine, an azide moiety). (A) Analysis of NAEK-dependent expression of VP1 proteins by Western blotting. GAPDH was used as an internal control; (B) Western blotting analysis of site-specific PEGylation of VP1 proteins with the S452+1 mutant chosen as a representative; (C) Transmission electron microscope (TEM) images of naked or PEGylated rAAV2 vectors (a, b: unmodified particles; c: particle modified with 20-kD PEG).
Figure 2 Feasibility of site-specific PEGylation of AAV capsid protein VP1 and AAV vectors by incorporation of NAEK (Nε-2-azideoethyloxycarbonyl-L-lysine, an azide moiety). (A) Analysis of NAEK-dependent expression of VP1 proteins by Western blotting. GAPDH was used as an internal control; (B) Western blotting analysis of site-specific PEGylation of VP1 proteins with the S452+1 mutant chosen as a representative; (C) Transmission electron microscope (TEM) images of naked or PEGylated rAAV2 vectors (a, b: unmodified particles; c: particle modified with 20-kD PEG).CC BY · PubMed Central
Figure 3 Comparing the effect of NAEK incorporation at different sites on the production and infectivity of rAAV2 vectors. (A) Viral packaging efficiency of site-specific NAEK rAAV2 mutants was measured by qPCR as the number of packaged genome copies/mL and normalized to that of the wild type; (B) The viral infectivity of site-specific NAEK mutants of rAAV2 vectors, which was calculated as the ratios of functional titers (transgene expression detected by luciferase assay on HT-1080 cells) to genomic titers and finally normalized to that of the wild-type group. Data represent the average values and standard deviations from triplicate experiments.
Figure 3 Comparing the effect of NAEK incorporation at different sites on the production and infectivity of rAAV2 vectors. (A) Viral packaging efficiency of site-specific NAEK rAAV2 mutants was measured by qPCR as the number of packaged genome copies/mL and normalized to that of the wild type; (B) The viral infectivity of site-specific NAEK mutants of rAAV2 vectors, which was calculated as the ratios of functional titers (transgene expression detected by luciferase assay on HT-1080 cells) to genomic titers and finally normalized to that of the wild-type group. Data represent the average values and standard deviations from triplicate experiments.CC BY · PubMed Central
Figure 4 The effect of PEGylation on rAAV2 infectivity and stability in human serum. (A) Effect of PEGylation on in vitro transduction efficiency of rAAV2; (B) Effect of site-specific PEGylation on rAAV2 stability in human serum in vitro. PEGylated/naked rAAV2 vectors were incubated in pooled human serum/PBS and then used to infect HT1080 cells, as measured by an increase in fluorescence. The retained activity was calculated by an equation described in Section 4.8 and normalized to that of the wild-type control. All quantitative data shown are average values with standard deviations from triplicate experiments. A two-sample t-test was used to determine the statistical differences among the groups at the same time point. *** p < 0.001, ** p < 0.01, * p < 0.05.
Figure 4 The effect of PEGylation on rAAV2 infectivity and stability in human serum. (A) Effect of PEGylation on in vitro transduction efficiency of rAAV2; (B) Effect of site-specific PEGylation on rAAV2 stability in human serum in vitro. PEGylated/naked rAAV2 vectors were incubated in pooled human serum/PBS and then used to infect HT1080 cells, as measured by an increase in fluorescence. The retained activity was calculated by an equation described in Section 4.8 and normalized to that of the wild-type control. All quantitative data shown are average values with standard deviations from triplicate experiments. A two-sample t-test was used to determine the statistical differences among the groups at the same time point. *** p < 0.001, ** p < 0.01, * p < 0.05.CC BY · PubMed Central
Figure 5 In vitro evaluation for PEGylated rAAV2 at sites Q325+1, S452+1, and R585+1 using 5-kD, 10-kD, 20-kD, and 40-kD PEG. (A) Transduction efficiency of rAAV2 modified with PEG of different molecular weights; (B) Effect of PEGylation size on the in vitro stability of rAAV2 in pooled human serum; (C) Site-specific PEGylation at Q325+1, S452+1, and R585+1 protects rAAV2 from recognition by antibodies in vitro. The affinity between anti-AAV polyclonal antibody and rAAV2 vectors modified/not modified with 20-kD PEG was determined by the enzyme-linked immunosorbent assay. Optical densities at 450 nm are shown. All quantitative data shown are average values with standard deviations from triplicate experiments. A two-sample t-test was used to determine statistical differences. *** p < 0.001, ** p < 0.01, * p < 0.05.
Figure 5 In vitro evaluation for PEGylated rAAV2 at sites Q325+1, S452+1, and R585+1 using 5-kD, 10-kD, 20-kD, and 40-kD PEG. (A) Transduction efficiency of rAAV2 modified with PEG of different molecular weights; (B) Effect of PEGylation size on the in vitro stability of rAAV2 in pooled human serum; (C) Site-specific PEGylation at Q325+1, S452+1, and R585+1 protects rAAV2 from recognition by antibodies in vitro. The affinity between anti-AAV polyclonal antibody and rAAV2 vectors modified/not modified with 20-kD PEG was determined by the enzyme-linked immunosorbent assay. Optical densities at 450 nm are shown. All quantitative data shown are average values with standard deviations from triplicate experiments. A two-sample t-test was used to determine statistical differences. *** p < 0.001, ** p < 0.01, * p < 0.05.CC BY · PubMed Central
Figure 6 In vivo evaluation of PEGylated rAAV2 elimination in blood and antibody inducement using a Sprague Dawley rat model. (A) Blood clearance curve of PEGylated rAAV2. The genomic titer of retained rAAV2 in the blood at each time point was measured by quantitative PCR after a single dose injection of rAAV2, then normalized to that of wild type (WT) at 1 min; (B) Antibody induction experiment of PEGylated rAAV2 for a one-month period involving repeated stimulation. The level of VP1-specific antibodies in the blood at each time point was determined by an ELISA assay and presented in the form of normalized optical densities at 450 nm. All quantitative data shown are the average values with standard deviations from triplicate experiments. A two-sample t-test was used to determine the statistical difference among the groups at the same time point. *** p < 0.001, ** p < 0.01, * p < 0.05.
Figure 6 In vivo evaluation of PEGylated rAAV2 elimination in blood and antibody inducement using a Sprague Dawley rat model. (A) Blood clearance curve of PEGylated rAAV2. The genomic titer of retained rAAV2 in the blood at each time point was measured by quantitative PCR after a single dose injection of rAAV2, then normalized to that of wild type (WT) at 1 min; (B) Antibody induction experiment of PEGylated rAAV2 for a one-month period involving repeated stimulation. The level of VP1-specific antibodies in the blood at each time point was determined by an ELISA assay and presented in the form of normalized optical densities at 450 nm. All quantitative data shown are the average values with standard deviations from triplicate experiments. A two-sample t-test was used to determine the statistical difference among the groups at the same time point. *** p < 0.001, ** p < 0.01, * p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Fields, B., Knipe, D., Howley, P., and Griffin, D. (2007). Fields Virology, Lippincott Williams & Wilkins. [5th ed.].
  2. Muzyczka, 2001, Parvoviridae: The viruses and their replication, Fields Virol., 2, 2327

Cited by

Metadata

Authors
Yao, T., Zhou, X., Zhang, C., Yu, X., Tian, Z., Zhang, L., & Zhou, D.
Affiliations
Peking University (CN)
Corresponding author
  • Zhang, Chuanling
  • Zhou, Demin
Venue
Molecules
Publisher
MDPI AG
Published
2017-07-11
Volume
22
Issue
7
Pages
1155
ISSN
1420-3049 (ISSN-L)
OpenAlex
W2735631314
Cited by
68
References
35
Citations by year
2026: 10 · 2025: 13 · 2024: 11 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5
FWCI
2.72
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81530090, 81673342, 81361168002, 2016YFA0501500)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
adeno-associated virus, site-specific PEGylation, genetic code expansion, click chemistry, serum stability, immunogenicity, antibody neutralization, gene therapy vectors, blood clearance
MeSH terms
Dependovirus, Animals, Antibody Formation, Binding Sites, Cell Line, Genetic Vectors, Humans, Immunity, Active, Male, Mutation, Polyethylene Glycols, Surface Properties, Rats, Sprague-Dawley, Gene Transfer Techniques, Capsid Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.